Enhancing TCR-T Activity through Target Selection, Synthetic Biology, & Non-Viral Gene Editing for Solid Tumor Treatment
Time: 1:55 pm
day: Conference Day One
Details:
• Discuss how targeting oncodriver mutations for which the cancer has established genetic dependency can limit tumor escape and avoid on-target/off-tumor toxicities
• Highlight the incorporation of novel chimeric fusion proteins that can enable TCR-Ts to overcome unfavorable solid tumor microenvironments
• Discuss the added benefit of non-viral gene-editing to improve the anti-tumor activity and manufacturing of TCR-Ts
